Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 152

1.

The Fanconi anemia (FA) pathway confers glioma resistance to DNA alkylating agents.

Chen CC, Taniguchi T, D'Andrea A.

J Mol Med (Berl). 2007 May;85(5):497-509. Epub 2007 Jan 13.

PMID:
17221219
2.

FANCD2 re-expression is associated with glioma grade and chemical inhibition of the Fanconi Anaemia pathway sensitises gliomas to chemotherapeutic agents.

Patil AA, Sayal P, Depondt ML, Beveridge RD, Roylance A, Kriplani DH, Myers KN, Cox A, Jellinek D, Fernando M, Carroll TA, Collis SJ.

Oncotarget. 2014 Aug 15;5(15):6414-24.

3.

Inhibition of DNA-repair genes Ercc1 and Mgmt enhances temozolomide efficacy in gliomas treatment: a pre-clinical study.

Boccard SG, Marand SV, Geraci S, Pycroft L, Berger FR, Pelletier LA.

Oncotarget. 2015 Oct 6;6(30):29456-68. doi: 10.18632/oncotarget.4909.

4.

N-methylpurine DNA glycosylase and DNA polymerase beta modulate BER inhibitor potentiation of glioma cells to temozolomide.

Tang JB, Svilar D, Trivedi RN, Wang XH, Goellner EM, Moore B, Hamilton RL, Banze LA, Brown AR, Sobol RW.

Neuro Oncol. 2011 May;13(5):471-86. doi: 10.1093/neuonc/nor011. Epub 2011 Mar 3.

5.

DNA-Targeted Inhibition of MGMT.

Marsoner T, Schmidt OP, Triemer T, Luedtke NW.

Chembiochem. 2017 May 18;18(10):894-898. doi: 10.1002/cbic.201600652. Epub 2017 Apr 7.

PMID:
28177192
6.

Enhanced cytotoxic effect of radiation and temozolomide in malignant glioma cells: targeting PI3K-AKT-mTOR signaling, HSP90 and histone deacetylases.

Choi EJ, Cho BJ, Lee DJ, Hwang YH, Chun SH, Kim HH, Kim IA.

BMC Cancer. 2014 Jan 13;14:17. doi: 10.1186/1471-2407-14-17.

7.

Transfection of a human glioblastoma cell line with liver-type glutaminase (LGA) down-regulates the expression of DNA-repair gene MGMT and sensitizes the cells to alkylating agents.

Szeliga M, Zgrzywa A, Obara-Michlewska M, Albrecht J.

J Neurochem. 2012 Nov;123(3):428-36. doi: 10.1111/j.1471-4159.2012.07917.x. Epub 2012 Sep 21.

8.

Temozolomide: mechanisms of action, repair and resistance.

Zhang J, Stevens MF, Bradshaw TD.

Curr Mol Pharmacol. 2012 Jan;5(1):102-14.

PMID:
22122467
9.

Effect of IFN-beta on human glioma cell lines with temozolomide resistance.

Yoshino A, Ogino A, Yachi K, Ohta T, Fukushima T, Watanabe T, Katayama Y, Okamoto Y, Naruse N, Sano E.

Int J Oncol. 2009 Jul;35(1):139-48.

PMID:
19513561
11.

Inhibition of GSH synthesis potentiates temozolomide-induced bystander effect in glioblastoma.

Kohsaka S, Takahashi K, Wang L, Tanino M, Kimura T, Nishihara H, Tanaka S.

Cancer Lett. 2013 Apr 30;331(1):68-75. doi: 10.1016/j.canlet.2012.12.005. Epub 2012 Dec 12.

PMID:
23246370
12.

Alkylpurine-DNA-N-glycosylase confers resistance to temozolomide in xenograft models of glioblastoma multiforme and is associated with poor survival in patients.

Agnihotri S, Gajadhar AS, Ternamian C, Gorlia T, Diefes KL, Mischel PS, Kelly J, McGown G, Thorncroft M, Carlson BL, Sarkaria JN, Margison GP, Aldape K, Hawkins C, Hegi M, Guha A.

J Clin Invest. 2012 Jan;122(1):253-66. doi: 10.1172/JCI59334. Epub 2011 Dec 12. Erratum in: J Clin Invest. 2012 Feb 1;122(2):782.

13.

Rad51 inhibition is an effective means of targeting DNA repair in glioma models and CD133+ tumor-derived cells.

Short SC, Giampieri S, Worku M, Alcaide-German M, Sioftanos G, Bourne S, Lio KI, Shaked-Rabi M, Martindale C.

Neuro Oncol. 2011 May;13(5):487-99. doi: 10.1093/neuonc/nor010. Epub 2011 Mar 1.

14.

Inhibition of DNA repair for sensitizing resistant glioma cells to temozolomide.

Kanzawa T, Bedwell J, Kondo Y, Kondo S, Germano IM.

J Neurosurg. 2003 Dec;99(6):1047-52.

PMID:
14705733
15.

mTOR inhibition and levels of the DNA repair protein MGMT in T98G glioblastoma cells.

Smalley S, Chalmers AJ, Morley SJ.

Mol Cancer. 2014 Jun 8;13:144. doi: 10.1186/1476-4598-13-144.

16.

Distinct molecular mechanisms of acquired resistance to temozolomide in glioblastoma cells.

Happold C, Roth P, Wick W, Schmidt N, Florea AM, Silginer M, Reifenberger G, Weller M.

J Neurochem. 2012 Jul;122(2):444-55. doi: 10.1111/j.1471-4159.2012.07781.x. Epub 2012 May 28.

17.

Gene expression profiling predicts response to temozolomide in malignant gliomas.

Yoshino A, Ogino A, Yachi K, Ohta T, Fukushima T, Watanabe T, Katayama Y, Okamoto Y, Naruse N, Sano E, Tsumoto K.

Int J Oncol. 2010 Jun;36(6):1367-77.

PMID:
20428759
18.

O6-methylguanine-DNA methyltransferase, O6-benzylguanine, and resistance to clinical alkylators in pediatric primary brain tumor cell lines.

Bobola MS, Silber JR, Ellenbogen RG, Geyer JR, Blank A, Goff RD.

Clin Cancer Res. 2005 Apr 1;11(7):2747-55.

19.

Carmustine-resistant cancer cells are sensitized to temozolomide as a result of enhanced mismatch repair during the development of carmustine resistance.

Yamauchi T, Ogawa M, Ueda T.

Mol Pharmacol. 2008 Jul;74(1):82-91. doi: 10.1124/mol.107.041988. Epub 2008 Apr 22.

Supplemental Content

Support Center